跳至主要内容
临床试验/NCT06843265
NCT06843265尚未招募不适用

Outcomes and Perceptions of the Implementation of the JADA Device in a Stage II Postpartum Hemorrhage Management Protocol in Referral Hospitals of the Colombian Pacific Region: a Cohort Study

Fundacion Clinica Valle del Lili0 个研究点目标入组 24 人开始时间: 2025年6月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
24
主要终点
Bleeding control

研究概览

简要总结

This study focuses on postpartum hemorrhage (PPH), a condition that stands out as the leading cause of global maternal mortality. Annually, about 14 million women experience PPH, resulting in approximately 70,000 deaths. This condition presents a higher risk in low- and middle-income countries (LMICs), particularly where access to quality care is limited. Recognizing the urgency of addressing this public health problem, the Colombian Ministry of Health and Social Protection has implemented the Maternal Mortality Reduction Acceleration Plan (PARE) to improve maternal mortality indicators and meet the Sustainable Development Goals (SDGs).

The project will evaluate the results and perception of a new device in the management of stage II PPH in referral hospitals in the department of Valle del Cauca, integrated in the Hospital Padrino strategy. This initiative seeks not only to improve the understanding and treatment of PPH, but also to strengthen institutional capacities through education, creation of telecare networks and care services adapted to local needs.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者
否

入选标准

  • •Pregnant women who are admitted to the obstetrics service scheduled for vaginal delivery in any of the participating hospitals: Fundación Valle del Lili, Hospital Universitario del Valle and Hospital Luis Ablanque de la Plata.
  • •Patient admitted during the shift of one of the gynecologists trained in the use of the JADA device in the context of the research project.
  • •Criteria for the use of JADA device:
  • •Pregnant women over or equal to 18 years of age.
  • •Gestational age of pregnancy greater than 32 weeks of gestation.
  • •Pregnant with vaginal delivery.
  • •Pregnant with postpartum hemorrhage due to uterine atony that does not respond to treatment with uterotonics and uterine massage.
  • •Postpartum hemorrhage uterine stage/stage II.
  • •Vaginal delivery attended in a health institution in the context of the Hospital Padrino strategy (Fundación Valle del Lili or Hospital Universitario del Valle or Hospital Luis Ablanque de la Plata).

排除标准

  • •Patients who, according to the attending physician's criteria, are not candidates for vaginal delivery.
  • •Abnormality of the normal uterine anatomy.
  • •Placental abnormalities.
  • •Maternal anemia with hemoglobin less than 7 mg/dl prior to delivery.
  • •Those who do not sign informed consent.

研究组 & 干预措施

Group 1

Experimental

Pregnant women with stage II postpartum hemorrhage, after vaginal delivery, who have had the JADA device implemented and meet INVIMA's definition of use of the instrument: the JADA system is intended to provide control and treatment of abnormal postpartum uterine bleeding or postpartum hemorrhage when conservative management is warranted, attended in hospitals in the context of the Godfather Hospital Strategy in the department of Valle del Cauca.

干预措施: Vacuum- Induce Hemorrhage Control (Device)

结局指标

主要结局

Bleeding control

时间窗: up to 42 days postpartum

Postpartum hemorrhage defined as quantified bleeding of more than 500 ml for vaginal deliveries and more than 1000 ml for cesarean deliveries, occurring within the first 24 h after delivery and which may be associated with signs of hemodynamic instability, i.e. the ratio between heart rate and systolic blood pressure (shock index). Following this concept of the shock index and the amount of bleeding, the stages of postpartum hemorrhage are divided, which, according to the result of the shock index, the therapy is directed: Stage 1: Bleeding 500-1000 cc, Shock index of \<0.9, bleeding time \<10 minutes. Stage 2: Bleeding 1000-1500 cc, shock index 0.9-1.4 bleeding time 10-20 minutes. Stage 3: Bleeding \<1500 cc, shock index \>1.5, bleeding time greater than 20 minutes. Stage 4: Cardiovascular collapse with profound hypovolemic shock and coagulopathy. These stages will be measured through a bag which will fulfill the function of measuring to indicate the stage and amount of bleeding

次要结局

未报告次要终点

研究者

发起方
Fundacion Clinica Valle del Lili
申办方类型
Other
责任方
Principal Investigator
主要研究者

María Fernanda Escobar

Global health equity unit director

Fundacion Clinica Valle del Lili

相似试验